id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-N-2462-0004,FDA,FDA-2016-N-2462,Reference 2 FDA Issues Public Advisory for Trasylol re Amendments to the Regulation Regarding the List of Drug Products That Have Been Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness,Supporting & Related Material,Background Material,2016-10-21T04:00:00Z,2016,10,,,2016-10-21T20:41:49Z,,0,0,0900006482337d47
FDA-2016-N-2462-0009,FDA,FDA-2016-N-2462,Reference 7 FDA Requests Marketing Suspension of Trasylol re Amendments to the Regulation Regarding the List of Drug Products That Have Been Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness,Supporting & Related Material,Background Material,2016-10-21T04:00:00Z,2016,10,,,2016-10-21T20:45:00Z,,0,0,0900006482337db7
FDA-2016-N-2462-0012,FDA,FDA-2016-N-2462,Reference 10 Fertility and Maternal Health Drugs Advisory Committee re Amendments to the Regulation Regarding the List of Drug Products That Have Been Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness,Supporting & Related Material,Background Material,2016-10-21T04:00:00Z,2016,10,,,2016-10-21T20:46:44Z,,0,0,0900006482337dba
FDA-2016-N-2462-0008,FDA,FDA-2016-N-2462,Reference 6 Safety Alerts for Human Medical Products re Amendments to the Regulation Regarding the List of Drug Products That Have Been Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness,Supporting & Related Material,Background Material,2016-10-21T04:00:00Z,2016,10,,,2016-10-21T20:44:38Z,,0,0,0900006482337db6
FDA-2016-N-2462-0011,FDA,FDA-2016-N-2462,Reference 9 Parlodel re Amendments to the Regulation Regarding the List of Drug Products That Have Been Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness,Supporting & Related Material,Background Material,2016-10-21T04:00:00Z,2016,10,,,2016-10-21T20:46:10Z,,0,0,0900006482337db9
FDA-2016-N-2462-0010,FDA,FDA-2016-N-2462,Reference 8 Manufacturer Removes Remaining Stocks of Trasylol re Amendments to the Regulation Regarding the List of Drug Products That Have Been Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness,Supporting & Related Material,Background Material,2016-10-21T04:00:00Z,2016,10,,,2016-10-21T20:45:23Z,,0,0,0900006482337db8
FDA-2016-N-2462-0015,FDA,FDA-2016-N-2462,Reference 13 FDA Drug Safety Communication re Amendments to the Regulation Regarding the List of Drug Products That Have Been Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness,Supporting & Related Material,Background Material,2016-10-21T04:00:00Z,2016,10,,,2016-10-21T20:47:57Z,,0,0,090000648233810d
FDA-2016-N-2462-0007,FDA,FDA-2016-N-2462,Reference 5 A Comparison of Aprotinin and Lysine Analogues in High-Risk re Amendments to the Regulation Regarding the List of Drug Products That Have Been Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness,Supporting & Related Material,Background Material,2016-10-21T04:00:00Z,2016,10,,,2016-10-21T20:44:16Z,,0,0,0900006482337db5
FDA-2016-N-2462-0013,FDA,FDA-2016-N-2462,Reference 11 FDA Drug Safety Communication re Amendments to the Regulation Regarding the List of Drug Products That Have Been Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness,Supporting & Related Material,Background Material,2016-10-21T04:00:00Z,2016,10,,,2016-10-21T20:47:12Z,,0,0,0900006482337dbc
FDA-2016-N-2462-0002,FDA,FDA-2016-N-2462,Reference List for 2015-609 re Amendments to the Regulation Regarding the List of Drug Products That Have Been Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness,Supporting & Related Material,Background Material,2016-10-21T04:00:00Z,2016,10,,,2016-10-21T20:41:00Z,,0,0,0900006482337d45
FDA-2016-N-2462-0006,FDA,FDA-2016-N-2462,Reference 4 Mortality Associated With Aprotinin re Amendments to the Regulation Regarding the List of Drug Products That Have Been Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness,Supporting & Related Material,Background Material,2016-10-21T04:00:00Z,2016,10,,,2016-10-21T20:43:45Z,,0,0,0900006482337db4
FDA-2016-N-2462-0003,FDA,FDA-2016-N-2462,Reference 1 The Risk Associated with Aprotinin in Cardiac Surgery re Amendments to the Regulation Regarding the List of Drug Products That Have Been Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness,Supporting & Related Material,Background Material,2016-10-21T04:00:00Z,2016,10,,,2016-10-21T20:43:14Z,,0,0,0900006482337d46
FDA-2016-N-2462-0005,FDA,FDA-2016-N-2462,Reference 3 Aprotinin during Coronary-Artery Bypass Grafting and Risk of re Amendments to the Regulation Regarding the List of Drug Products That Have Been Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness,Supporting & Related Material,Background Material,2016-10-21T04:00:00Z,2016,10,,,2016-10-21T20:42:39Z,,0,0,0900006482337d48
FDA-2016-N-2462-0014,FDA,FDA-2016-N-2462,Reference 12 FDA Drug Safety Communication re Amendments to the Regulation Regarding the List of Drug Products That Have Been Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness,Supporting & Related Material,Background Material,2016-10-21T04:00:00Z,2016,10,,,2016-10-21T20:47:36Z,,0,0,090000648233810c
FDA-2016-N-2462-0001,FDA,FDA-2016-N-2462,"Amendments to the Regulation Regarding the List of Drug Products
That Have Been Withdrawn or Removed From the Market for Reasons
of Safety or Effectiveness",Proposed Rule,Amendment,2016-10-18T04:00:00Z,2016,10,2016-10-18T04:00:00Z,2017-01-04T04:59:59Z,2016-12-29T14:00:42Z,2016-25005,0,0,090000648230f5e5